Related Experiment Video
Updated: Feb 10, 2026

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer
Anne Serrao1, Laura M Jenkins1, Alexander A Chumanevich2
1Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, USA.
Abstract:
CDK8 is a transcription-regulating kinase that controls TGF-β/BMP-responsive SMAD transcriptional activation and turnover through YAP1 recruitment. However, how the CDK8/YAP1 pathway influences SMAD1 response in cancer remains unclear. Here we report that SMAD1-driven epithelial-to-mesenchymal transition (EMT) is critically dependent on matrix rigidity and YAP1 in a wide spectrum of cancer models. We find that both genetic and pharmacological inhibition of CDK8 and its homologous twin kinase CDK19 leads to abrogation of BMP-induced EMT. Notably, selectively blocking CDK8/19 specifically abrogates tumor cell invasion, changes in EMT-associated transcription factors, E-cadherin expression and YAP nuclear localization both in vitro and in vivo in a murine syngeneic EMT model. Furthermore, RNA-seq meta-analysis reveals a direct correlation between CDK8 and EMT-associated transcription factors in patients. Our findings demonstrate that CDK8, an emerging therapeutic target, coordinates growth factor and mechanical cues during EMT and invasion.
Insights
Cyclin-dependent kinase 8 (CDK8) and CDK19 inhibition block cancer cell invasion by disrupting the SMAD1-driven epithelial-to-mesenchymal transition (EMT) pathway, highlighting CDK8 as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Cyclin-dependent kinase 8 (CDK8) regulates transcription and is implicated in cancer.
- The interplay between CDK8, YAP1, and SMAD1 in cancer-related epithelial-to-mesenchymal transition (EMT) is not fully understood.
Purpose of the Study:
- To investigate the role of the CDK8/YAP1 pathway in SMAD1-driven EMT and cancer invasion.
- To determine the therapeutic potential of targeting CDK8/19 in cancer.
Main Methods:
- Utilized various cancer models, including in vitro and in vivo murine syngeneic models.
- Employed genetic and pharmacological inhibition of CDK8 and CDK19.
- Performed RNA-sequencing meta-analysis.
Main Results:
- SMAD1-driven EMT is dependent on matrix rigidity and YAP1.
- Inhibition of CDK8/19 abrogates BMP-induced EMT, tumor cell invasion, and EMT-associated transcription factor changes.
- CDK8 inhibition reduces YAP nuclear localization and E-cadherin expression.
- A correlation exists between CDK8 expression and EMT transcription factors in patients.
Conclusions:
- CDK8 coordinates growth factor and mechanical signals during EMT and invasion.
- Targeting CDK8/19 presents a promising therapeutic strategy for inhibiting cancer cell invasion.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
Mechanisms of Retrovirus-induced Cancers
Receptor Tyrosine Kinases
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

